Cathie Wood’s ARK Invest Shifts Portfolio: Boosts Biotech, Trims Tech
Cathie Wood's ARK Invest made significant portfolio adjustments on October 28, 2025, doubling down on biotech while reducing exposure to tech favorites. The firm added $16.46 million in DraftKings shares across three ETFs, signaling confidence in the sports betting sector as regulatory barriers fall. Gene-editing pioneer Intellia Therapeutics saw a $7.09 million infusion, reinforcing ARK's conviction in CRISPR technologies.
Meanwhile, the investment manager continued unwinding positions in Shopify and Palantir, reflecting a strategic rotation from mature tech plays to disruptive healthcare innovations. The moves highlight ARK's signature focus on paradigm-shifting technologies, though notably absent any cryptocurrency-related adjustments in this trading session.